Novo Nordisk CEO: "We are very encouraged by growth momentum"

A theme of Novo Nordisk’s capital markets day on Thursday is how to stay on the current growth track in the future, says CEO Lars Fruergaard Jørgensen.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH

Pharmaceutical firm Novo Nordisk’s sales growth has accelarated since 2019, when it introduced new financial targets and ambitions for 2025. A theme of the company’s capital markets day, which is taking place at the time of writing on Thursday, is how to continue on this track.

”We are very encouraged by the growth momentum we have now. Today, we will try to explain how we believe we can maintain that growth and how we can drive growth within diabetes and obesity (two of Novo’s business areas, ed.) by maximizing semaglutide’s potential in the short and medium term,” says Novo Nordisk CEO Lars Fruergaard Jørgensen at the meeting.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs